Luis Martinez, MD
Internal Medicine · Doral, FLNPI 1972605533
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,432 of the $3,293 with a category attached, or 73.8%. 23 manufacturers reported payments, led by Modernatx, Inc. at 35.2% of the total. Reporting peaked in 2024 at $1,327 and has fallen 67.1% since, to $436 in 2025.
Across 109 payments — averaging $30.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$1K
- Novo Nordisk$414
- Amgen$247
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$187
- Sight Sciences, Inc.$142
- Astrazeneca UK Limited$135
- plus $1K from 17 others
Across 602 payments — averaging $22,961 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$5.3M
- Genentech, Inc.$2.8M
- Modernatx, Inc.$2.2M
- Abbott$860K
- GSK$736K
- AbbVie$543K
- plus $1.4M from 16 others
What the payments were for
- Travel & lodging$85326%
- Food & beverage$2,43274%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 8 | $1,159 |
| Novo Nordisk | 20 | $414 |
| Amgen | 16 | $247 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $187 |
| Sight Sciences, Inc. | 1 | $142 |
| Astrazeneca UK Limited | 3 | $135 |
| Teva Pharmaceuticals USA, Inc. | 6 | $135 |
| Pfizer | 8 | $125 |
| Exact Sciences | 4 | $101 |
| Lilly USA, LLC | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 3 | $75 |
| AbbVie | 4 | $73 |
| Abbott | 4 | $72 |
| Intuitive Surgical | 1 | $60 |
| Boehringer Ingelheim | 2 | $49 |
| GSK | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $38 |
| AstraZeneca | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Novartis | 1 | $23 |
| Gilead | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,293 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 40 | $56,333 |
| OzempicSemaglutide | 47 | $50,187 |
| LinzessLinaclotide | 62 | $45,507 |
| ProliaDenosumab | 20 | $36,237 |
| LevocarnitineLevocarnitine (With Sugar) | 85 | $33,426 |
| EliquisApixaban | 55 | $31,784 |
| FarxigaDapagliflozin Propanediol | 36 | $29,428 |
| Lactulose | 294 | $27,549 |
| EntrestoSacubitril/Valsartan | 22 | $27,422 |
| VascepaIcosapent Ethyl | 46 | $17,939 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $14,162 |
| Gabapentin | 96 | $11,332 |
| TradjentaLinagliptin | 12 | $6,834 |
| ErtapenemErtapenem Sodium | 12 | $6,372 |
| Levetiracetam | 92 | $5,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $49 | $63,16752 claims |
| AbbVieLinzess, Synthroid | $73 | $50,34097 claims |
| Novo NordiskOzempic | $414 | $50,18747 claims |
| AmgenProlia | $247 | $36,23720 claims |
| AstraZenecaFarxiga, Symbicort | $35 | $33,26148 claims |
| PfizerEliquis | $125 | $31,78455 claims |
| NovartisEntresto | $23 | $27,42222 claims |
| GSKBreo Ellipta | $46 | $14,16229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Doral
- Ludmila de la ConcepcionDoral$101K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.